GlobeNewswire by notified

Aktia and Käärijä encourage children and young people to learn about finances


Aktia Bank Plc
Press release
19 May 2023 at 4.45 p.m.

Aktia and Käärijä encourage children and young people to learn about finances

The runner up in the Eurovision Song Contest 2023, Käärijä, or Jere Pöyhönen, and Aktia, are working together to improve the financial literacy of children and young people. Good financial literacy is an important civic skill that increases equality in society.

Acquiring skills in using money and understanding the importance of good housekeeping at a young age builds a strong foundation for life. Practical financial skills are best learnt in everyday life by using money, and the learning process can also be interesting and fun.

As a wealth manager bank, Aktia wants to create wealth for the Finnish people and hence for society as a whole.

“Good financial literacy is important civic knowledge that increases equality in society. The foundation for managing and developing one's own finances is built during one’s childhood, as the understanding acquired helps shape one's own relationship with money and how it’s used. Children can start saving purposefully from an early age, and the bar can be raised as they get older," says Sam Olin, Director of Aktia's Asset Management Banking Services.

Käärijä wants to increase the financial literacy of children and young people

Käärijä and his song Cha Cha Cha have taken Europe and the world by storm and made Finnish music history. As a successful artist, he realizes how important it is to be able to manage one’s finances properly.

“I have been making music for a long time and now the hard work is starting to pay off financially. It enables me to do many things and I want to plan carefully how to make for example my dream of buying my own home come true", says Jere "Käärijä" Pöyhönen.

He became a customer at Aktia because he values having a personal contact person and individual high-quality counselling.

“We all have our strengths, and we need each other. I want to get advice from those who know more about finances than I do. I am happy to be a role model for children and young people and perhaps give them new ideas. It is important to take care of your finances, and you must also dare to follow your dreams and goals, and be the person you are”, Pöyhönen points out.

Aktia and Käärijä are joining forces to make financial literacy a natural part of life for children and young people.

“It is great that Käärijä will be the face of our campaign for children and young people. The campaign, which is carried out among others in social media, provides concrete ideas, and examples, and reaches its target groups well. And the best part is that Aktia and Käärijä have the same green brand colour", says Anna Holtari, Director of Aktia's partnerships.

For more information:
Anna Holtari, Director of Aktia’s partnerships, tel. +358 40 566 4745, anna.holtari(at)
Mia Smeds, Head of External Communication at Aktia, tel. +358 44 546 0379, mia.smeds(at)

Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsinki, Turku, Tampere, Vaasa, and Oulu regions. Our award-winning asset management business sells investment funds also internationally. We employ approximately 900 people around Finland. Aktia's assets under management (AuM) 31 December 2022 amounted to EUR 13.5 billion and the balance sheet total was EUR 12.4 billion. Aktia's shares are listed on Nasdaq Helsinki Ltd (AKTIA).


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ad hoc announcement: GAM Holding AG confirms the publication of the offer prospectus of Liontrust9.6.2023 07:00:00 CEST | Press release

9 June 2023 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM Holding AG confirmsthe publication of the offer prospectus of Liontrust Liontrust Asset Management PLc had previously stated that it intended to publish a Circular and the Offer Prospectus for the public exchange offer for all publicly held registered shares of GAM Holding AG on 9 June 2023. Liontrust Asset Management PLc now expects to publish both the Circular and Offer Prospectus on or around 13 June 2023. GAM is making this announcement pursuant to its obligations under Article 53 of the Listing Rules of the SIX Exchange. For further information please contact: Charles Naylor Head of Communications and Investor Relations T +44 7890 386 699 Media Relations Ute Dehn Christen T +41 58 426 31 36 Visit us: Follow us: Twitter and LinkedIn GAM GAM is an independent investment manager that is listed in Switzerland and has, within its Investment Management division, AuMA of CHF 23.3 billion (£21

Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release

Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release

FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris

DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release

Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n